CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

CytoSorbents (CTSO) will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York City on September 9-10, 2026.

Rhea-AI Summary

CytoSorbents (CTSO) will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York City on September 9-10, 2026. CEO Dr. Phillip Chan and CFO Peter Mariani will deliver an investor presentation and hold 1-on-1 meetings with investors.

The investor presentation is scheduled for Thursday, September 10, 2026 at 2:50 p.m. EST at The Westin New York Grand Central, 212 E 42nd St, New York, NY. The conference features company presentations, investor meetings, fireside chats, and capital markets panels focused on growth and life sciences companies.

Market Context

Insiders purchased 361,469 shares during the analyzed 90-day period, according to the platform recor...

Analysis

Insiders purchased 361,469 shares during the analyzed 90-day period, according to the platform record. That net buying contextualizes a visibility-focused conference appearance, while the company's stated lack of U.S. approval remains a risk to monitor.

Key Figures

Conference dates: September 9-10, 2026 Presentation date: September 10, 2026 Presentation time: 2:50pm EST +3 more

6 metrics

Conference dates September 9-10, 2026 Moody Capital Solutions 2026 conference

Presentation date September 10, 2026 Investor presentation

Presentation time 2:50pm EST Investor presentation

Countries reached Over 70 countries CytoSorb distribution

Devices used More than 300,000 devices Cumulative CytoSorb use

Breakthrough Device Designations Two DrugSorb-ATR indications

Historical Context

5 past events · Latest: Sep 03 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 03	Reverse stock split	Negative	-8.8%	One-for-twenty reverse split announced to support Nasdaq bid-price compliance.
Sep 02	Clinical data	Positive	+14.1%	Real-world CABG data showed reduced severe bleeding and supported a future FDA submission.
Aug 06	Second-quarter earnings	Negative	-9.7%	Revenue was flat year over year while the company reported a net loss.
Jul 20	Earnings date notice	Neutral	+5.6%	The company scheduled its second-quarter results release and investor conference call.
May 13	First-quarter earnings	Negative	-5.0%	Revenue increased modestly, but net loss and cash-burn disclosures accompanied regulatory plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

CTSO's recent news reactions were mixed, with positive clinical data followed by a 14.08% gain but both recent earnings reports followed by declines.

Key Terms

crrt, ecmo, ce mark, emergency use authorization, +1 more

5 terms

crrt medical

"dialysis, continuous renal replacement therapy or CRRT"

Continuous Renal Replacement Therapy (CRRT) is a hospital treatment that uses a machine to slowly and continuously filter a patient’s blood when the kidneys have failed, similar to a home water filter running all day instead of a quick rinse. For investors, CRRT signals demand for critical-care equipment, supplies and specialized staffing, and changes in its use or reimbursement can affect revenues and costs for medical-device makers, hospitals and dialysis service providers.

ecmo medical

"extracorporeal membrane oxygenation or ECMO"

Extracorporeal membrane oxygenation (ECMO) is a hospital-based life support system that temporarily takes over the job of the heart and lungs by circulating blood outside the body through a machine that adds oxygen and removes carbon dioxide. Think of it as an external engine that keeps oxygen flowing when a patient’s own organs are failing. For investors, ECMO signals high-cost, specialized care, drives demand for devices, training and disposables, and can affect hospital capacity, reimbursement and supplier revenue.

ce mark regulatory

"originally launched in the European Union under CE mark"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

emergency use authorization regulatory

"received FDA Emergency Use Authorization in the United States"

A regulatory emergency use authorization allows a government health agency to temporarily permit the use or sale of a medical product—such as a vaccine, test, or treatment—before full formal approval when there is a public health crisis. For investors, an authorization can rapidly open revenue and market access while carrying higher regulatory and demand risk, like a fast-track pass that speeds a product to customers but may still require further review and can affect a company's valuation and future sales prospects.

breakthrough device designation regulatory

"received two FDA Breakthrough Device Designations"

A breakthrough device designation is a regulatory program that gives promising medical devices for serious or life‑threatening conditions priority support and faster review from a health authority (e.g., the U.S. FDA). Think of it as a “fast lane” or VIP pass through development and review: it can shorten time to market, lower regulatory uncertainty, and boost a company’s commercial prospects — but it is not an approval by itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. Dr. Phillip Chan, CEO and Peter Mariani, CFO will be attending the conference, delivering an investor presentation and participating in scheduled 1-on-1 meetings with investors.

Investor Presentation:
Date: Thursday, September 10, 2026
Time: 2:50pm EST
Location: The Westin New York Grand Central, 212 E 42nd St, New York, NY
More info: https://moodycapital.com/conference/

About the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
The Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference brings together public and private growth companies, pioneering innovators, investors, C-suite executives and industry professionals across biotechnology, medical devices, pharmaceuticals, healthcare technology and other growth industries. The two-day conference features company presentations, one-on-one investor meetings, fireside chats, capital markets and financing panels, and networking opportunities with institutional investors and family offices.

About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb® was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb® has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb® is not yet approved or cleared in the United States.

In the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb®, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb®, ContrastSorb, PuriFi®, HotSwap™ and others. For more information, please visit the Company's website at https://ir.cytosorbents.com/ and follow us on Facebook and X and LinkedIn.

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval, our ability to reduce costs, optimize operations, and achieve cash-flow break-even in the second half of 2026, our ability to appropriately finance the Company, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and X and LinkedIn

Company Contact:
Peter J. Mariani, Chief Financial Officer
pmariani@cytosorbents.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312850

FAQ

When and where will CytoSorbents (CTSO) present at the Moody Capital 2026 Disruptive Growth & Life Sciences Conference?

CytoSorbents’ investor presentation is scheduled for Thursday, September 10, 2026 at 2:50 p.m. EST at The Westin New York Grand Central, 212 E 42nd St, New York, NY, during the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference.

Who from CytoSorbents (CTSO) will attend the Moody Capital 2026 Disruptive Growth & Life Sciences Conference?

CEO Dr. Phillip Chan and CFO Peter Mariani will attend on behalf of CytoSorbents. They will deliver the investor presentation and participate in scheduled one-on-one meetings with investors during the conference.

What is the focus of the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference that CytoSorbents (CTSO) is attending?

The conference focuses on growth and life sciences companies, bringing together public and private innovators, investors, and executives in biotechnology, medical devices, pharmaceuticals, and healthcare technology for presentations, investor meetings, fireside chats, and capital markets and financing panels.

How can investors find more information about the Moody Capital 2026 Disruptive Growth & Life Sciences Conference featuring CytoSorbents (CTSO)?

More information on the event is available at https://moodycapital.com/conference/. CytoSorbents also directs investors to its investor relations site at https://ir.cytosorbents.com/ for broader company and contact details.

What does CytoSorbents (CTSO) do in the field of blood purification?

CytoSorbents develops blood purification technologies using porous polymer bead cartridges to remove toxic substances from blood during intensive care and cardiac surgery. Its lead product, CytoSorb, is approved in the European Union and distributed in over 70 countries, with more than 300,000 devices used cumulatively.